1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Lung cancer

Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

Awaiting development [GID-TA11626] Expected publication date: TBC

  • Project information
  • Project documents

34848-Savolitinib-Osimertinib-for-Non-Small-Cell-Lung-Cancer-V1.0-JUL2024-NON-CONF.pdf (nihr.ac.uk)